BD Announces Results For 2012 Fourth Fiscal Quarter And Full Year

      BD Announces Results For 2012 Fourth Fiscal Quarter And Full Year

-- Adjusted fourth-quarter diluted earnings per share from continuing
operations of $1.42 exclude a $0.07 per share charge from primarily non-cash
pension settlements; reported earnings per share from continuing operations
were $1.35.

-- Expects full fiscal year 2013 reported diluted earnings per share from
continuing operations to be between $5.58 and $5.64, an increase of 4 to 5
percent. On a foreign currency-neutral basis, expects earnings per share to
grow between 7 to 8 percent, or 10 to 11 percent, after excluding the
estimated impact of the medical device tax.

-- Results reflect reclassification of Discovery Labware unit, excluding
Advanced Bioprocessing, as discontinued operations. The sale was completed on
October 31, 2012.

PR Newswire

FRANKLIN LAKES, N.J., Nov. 7, 2012

FRANKLIN LAKES, N.J., Nov. 7, 2012 /PRNewswire/ --BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company, today
reported quarterly revenues of $1.967 billion for the fourth fiscal quarter
ended September 30, 2012, representing a decrease of 1.1 percent from the
prior-year period, or an increase of 4.7 percent on a foreign currency-neutral
basis.

For the full fiscal year ended September 30, 2012, BD reported revenues of
$7.708 billion, representing an increase of 1.6 percent over the prior-year
period or 4.3 percent on a foreign currency-neutral basis.

"We are proud of our solid finish to 2012," said Vincent A. Forlenza, Chairman
of the Board, Chief Executive Officer and President. "Despite a challenging
macroeconomic environment, we delivered on our financial and operating goals
while continuing our ongoing investments in geographic expansion, new product
platforms and strategic acquisitions. We believe we are well positioned to
succeed and will continue to focus on our strategy of investing and innovating
for growth. We are confident in our outlook for fiscal year 2013 and remain
committed to delivering value to our customers and shareholders."

Sale of Discovery Labware Unit, Excluding Advanced Bioprocessing
In April 2012, the Company signed a definitive agreement to sell its BD
Biosciences - Discovery Labware unit, excluding its Advanced Bioprocessing
platform, to Corning Incorporated. The results of operations associated with
this disposal group have been reclassified as discontinued operations for all
quarters and years referred to in this release. The transaction was completed
on October 31, 2012 and the Company will record a gain within discontinued
operations in the first quarter of fiscal year 2013. 

Fourth Quarter and Analysis of the Full Fiscal Year 2012 and 2011 Earnings
Reported diluted earnings per share from continuing operations for the fourth
quarter were $1.35, representing an increase of 4.7 percent over the
prior-year period. Current quarter results included a charge of $20 million,
or $0.07 per share from continuing operations, resulting from primarily
non-cash pension settlements. The prior-year period results included a
non-cash charge of $9 million, or $0.03 per share from continuing operations,
resulting from the discontinuance of a research program within the Diagnostic
Systems unit. Excluding these items, adjusted diluted earnings per share from
continuing operations increased by 7.6 percent to $1.42, compared with $1.32
in the prior-year period. On a foreign currency-neutral basis, adjusted
diluted earnings per share from continuing operations for the fourth quarter
increased by 15.2 percent.

For the full fiscal year ended September 30, 2012, reported diluted earnings
per share from continuing operations were $5.30, representing a decrease of
0.2 percent over the prior-year period. Excluding the aforementioned charges
of $0.06 per share from continuing operations in fiscal year 2012, and $0.03
per share from continuing operations in fiscal year 2011, adjusted diluted
earnings per share from continuing operations increased by 0.8 percent to
$5.37, compared with $5.33 in the prior-year period. On a foreign
currency-neutral basis, adjusted diluted earnings per share from continuing
operations for the fiscal year increased 4.7 percent. On a full year basis,
the charge of $20 million, or $0.06 per share from continuing operations,
differs from the charge in the fourth quarter of $0.07 per share from
continuing operations due to the number of average shares outstanding between
the fourth quarter and full year.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $1.049
billion, representing a decrease of 0.5 percent compared with the prior-year
period, or an increase of 5.9 percent on a currency-neutral basis. The
segment's revenue growth reflected strong sales across all three business
units. For the twelve-month period ended September 30, 2012, BD Medical
revenues increased 2.1 percent, or 5.1 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $645
million, representing an increase of 0.5 percent compared with the prior-year
period, or 5.1 percent on a foreign currency-neutral basis. The segment's
growth was primarily driven by solid sales of Preanalytical Systems
safety-engineered products and strong sales in the Diagnostic Systems unit,
aided by the recent acquisition of KIESTRA. For the twelve-month period ended
September 30, 2012, BD Diagnostics revenues increased 2.3 percent, or 4.5
percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $273
million, representing a decrease of 6.3 percent compared with the prior-year
period, or 0.7 percent on a foreign currency-neutral basis. Segment results
continue to be negatively affected by weakness in the U.S. research market.
For the twelve-month period ended September 30, 2012, BD Biosciences revenues
decreased by 1.5 percent. On a foreign currency-neutral basis, revenues
increased by 0.7 percent.

Geographic Results
Fourth quarter revenues in the U.S. were $824 million, representing an
increase of 1.2 percent compared with the prior-year period. Revenues outside
of the U.S. were $1.143 billion, representing a decrease of 2.6 percent
compared with the prior-year period, or an increase of 7.1 percent on a
foreign currency-neutral basis. International revenues reflected continued
strength in emerging markets and strong sales of safety-engineered products.
For the twelve-month period ended September 30, 2012, revenues in the U.S.
were $3.288 billion, representing an increase of 1.2 percent compared with the
prior-year period. Revenues outside of the U.S. were $4.421 billion,
representing an increase of 1.9 percent compared with the prior-year period,
or 6.6 percent on a foreign currency-neutral basis.

Fiscal 2013 Outlook for Full Year
The Company estimates that reported revenues for the full fiscal year 2013
will increase 2 to 3 percent, or about 3.5 to 4.5 percent on a foreign
currency-neutral basis. The Company expects reported diluted earnings per
share from continuing operations for the full fiscal year 2013 to be between
$5.58 and $5.64. On a currency-neutral basis, the Company expects diluted
earnings per share from continuing operations to grow 7 to 8 percent, or 10 to
11 percent excluding the impact of the medical device tax that goes into
effect in January 2013 under the U.S. healthcare reform law. The Company also
plans to repurchase, subject to market conditions, about $500 million of its
common stock in 2013.

Conference Call Information
A conference call regarding BD's fourth quarter and full-year results and its
expectations for the full fiscal year 2013 will be broadcast live on BD's
website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET)
Wednesday, November 7, 2012. The conference call will be available for replay
on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and
1-404-537-3406 (international) through the close of business on Wednesday,
November 14, 2012, access code 35734482.

Non-GAAP Financial Measures
This news release contains certain non-GAAP financial measures.
Reconciliations of these and other non-GAAP measures to the comparable GAAP
measures are included in the attached financial tables.

About BD
BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents. The Company is
dedicated to improving people's health throughout the world. BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000
associates in more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please
visit www.bd.com.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5378
Colleen T. White, Corporate Communications – 201-847-5369

This press release, including the section entitled "Fiscal 2013 Outlook for
Full Year", contains certain estimates and other forward-looking statements
(as defined under Federal securities laws) regarding BD's performance,
including future revenues and earnings per share. All such statements are
based upon current expectations of BD and involve a number of business risks
and uncertainties. Actual results could vary materially from anticipated
results described, implied or projected in any forward-looking statement.
With respect to forward-looking statements contained herein, a number of
factors could cause actual results to vary materially from any forward-looking
statement. These factors include, but are not limited to: adverse changes in
regional, national or foreign economic conditions, including any impact that
may result from the current global economic conditions on our ability to
access credit markets and finance our operations, the demand for our products
and services as a result of reduced government funding, lower utilization
rates or otherwise, or our suppliers' ability to provide products needed for
our operations; the unknown consequences of healthcare reform in the United
States, including the impact of the reduction in Medicare and Medicaid
payments to hospitals, pharmaceutical companies and other customers, which
could reduce demand for our products and increase downward pricing pressure;
changes in interest or foreign currency exchange rates; competitive factors;
pricing and other market pressures; our ability to successfully integrate any
businesses we acquire; difficulties inherent in product development and delays
in product introductions; increases in energy costs and their effect on, among
other things, the cost of producing BD's products; fluctuations in costs and
availability of raw materials and in BD's ability to maintain favorable
supplier arrangements and relationships; new or changing laws impacting our
business or changes in enforcement practices with respect to such laws;
uncertainties of litigation (as described in BD's filings with the Securities
and Exchange Commission); future healthcare reform, including changes in
government pricing and reimbursement policies or other cost containment
reforms; the effects of potential pandemic diseases; and issuance of new or
revised accounting standards, as well as other factors discussed in BD's
filings with the Securities and Exchange Commission. We do not intend to
update any forward-looking statements to reflect events or circumstances after
the date hereof except as required by applicable laws or regulations.



BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)
                                         Three Months Ended September 30,
                                           2012        2011       % Change
REVENUES                                 $ 1,967,171 $ 1,988,181  (1.1)
Cost of products sold                      966,345     971,041    (0.5)
Selling and administrative                484,259     479,591    1.0
Research and development                   127,787     124,528    2.6
TOTAL OPERATING COSTS
 AND EXPENSES                          1,578,391   1,575,160  0.2
OPERATING INCOME                           388,780     413,021    (5.9)
Interest income                            11,954      1,915       NM
Interest expense                           (35,292)    (22,334)   58.0
Other (expense) income, net                (3,543)     1,272       NM
INCOME FROM CONTINUING OPERATIONS BEFORE
 INCOME TAXES                          361,899     393,874    (8.1)
Income tax provision                       87,621      108,827    (19.5)
INCOME FROM CONTINUING OPERATIONS          274,278     285,047    (3.8)
INCOME FROM DISCONTINUED OPERATIONS
 NET OF INCOME TAX PROVISION OF
$9,108 AND $8,860, RESPECTIVELY            14,765      14,933     (1.1)
NET INCOME                               $ 289,043   $ 299,980    (3.6)
EARNINGS PER SHARE
Basic:
Income from continuing operations        $ 1.38      $ 1.32       4.5
Income from discontinued operations      $ 0.07      $ 0.07       -
Net income (1)                           $ 1.45      $ 1.38       5.1
Diluted:
Income from continuing operations        $ 1.35      $ 1.29       4.7
Income from discontinued operations      $ 0.07      $ 0.07       -
Net income (1)                           $ 1.43      $ 1.36       5.1
AVERAGE SHARES OUTSTANDING
 Basic                                 199,072     216,726
 Diluted                               202,439     220,859
NM - Not Meaningful
(1) Total per share amounts may not add
due to rounding.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)
                                         Twelve Months Ended September 30,
                                           2012        2011       % Change
REVENUES                                 $ 7,708,382 $ 7,584,037  1.6
Cost of products sold                      3,755,388   3,625,122  3.6
Selling and administrative                1,923,354   1,823,537  5.5
Research and development                   471,755     469,517    0.5
TOTAL OPERATING COSTS
 AND EXPENSES                          6,150,497   5,918,176  3.9
OPERATING INCOME                           1,557,885   1,665,861  (6.5)
Interest income                            50,333      43,209     16.5
Interest expense                           (134,658)   (84,019)   60.3
Other expense, net                         (1,152)     (7,164)    (83.9)
INCOME FROM CONTINUING OPERATIONS BEFORE
 INCOME TAXES                          1,472,408   1,617,887  (9.0)
Income tax provision                       362,880     417,004    (13.0)
INCOME FROM CONTINUING OPERATIONS          1,109,528   1,200,883  (7.6)
INCOME FROM DISCONTINUED OPERATIONS
 NET OF INCOME TAX PROVISION OF
$31,268 AND $35,199, RESPECTIVELY          60,399      70,111     (13.9)
NET INCOME                               $ 1,169,927 $ 1,270,994  (8.0)
EARNINGS PER SHARE
Basic:
Income from continuing operations        $ 5.40      $ 5.43       (0.6)
Income from discontinued operations      $ 0.29      $ 0.32       (9.4)
Net income                               $ 5.69      $ 5.75       (1.0)
Diluted:
Income from continuing operations        $ 5.30      $ 5.31       (0.2)
Income from discontinued operations      $ 0.29      $ 0.31       (6.5)
Net income                              $ 5.59      $ 5.62       (0.5)
AVERAGE SHARES OUTSTANDING
 Basic                                 205,460     221,175
 Diluted                               209,181     226,280

Becton Dickinson and Company
Supplemental Income Statement Information - Fiscal 2012
Revised for discontinued operations of Discovery Labware divestiture
(Unaudited: Amounts in thousands, except per-share data)
                                               Amounts
                                               reclassified to     From
                                               Discontinued       Continuing
                                 Pro Forma     Operations          Operations
Quarter 1
Revenues                      $  1,887,645  $  55,925           $  1,831,720
Income                       $  263,010    $  14,466           $  248,544
Diluted Earnings Per Share    $  1.21       $  0.07             $  1.14
Quarter 2
Revenues                      $  1,990,818  $  61,857           $  1,928,961
Income                       $  290,548    $  15,424           $  275,124
Diluted Earnings Per Share    $  1.38       $  0.07             $  1.31
Quarter 3
Revenues                      $  2,040,760  $  60,230           $  1,980,530
Income                       $  326,795    $  15,214           $  311,581
Diluted Earnings Per Share    $  1.59       $  0.07             $  1.52
Quarter 4
Revenues                      $  2,027,335  $  60,164           $  1,967,171
Income                       $  289,099    $  14,821           $  274,278
Diluted Earnings Per Share    $  1.43       $  0.07             $  1.35
(1)
YTD
Revenues                      $  7,946,559  $  238,177          $  7,708,382
Income                       $  1,169,453  $  59,925           $  1,109,528
Diluted Earnings Per Share   $  5.59       $  0.29             $  5.30
Certain quarterly amounts may not add to the year-to-date totals due to
rounding.
(1) Diluted Earnings per Share may not add due to rounding.

Becton Dickinson and Company
Supplemental Income Statement Information - Fiscal 2011 and 2010
Revised for discontinued operations of Discovery Labware divestiture
(Unaudited: Amounts in thousands, except per-share data)
                                         Amounts
                                         reclassified to   From
                                         Discontinued     Continuing
                             Pro Forma   Operations        Operations
Fiscal 2011
Revenues                   $ 7,828,904 $ 244,867         $ 7,584,037
Income                    $ 1,264,852 $ 63,969          $ 1,200,883
Diluted Earnings Per Share $ 5.59      $ 0.28            $ 5.31
Fiscal 2010
Revenues                   $ 7,372,333 $ 247,948         $ 7,124,385
Income                    $ 1,176,340 $ 61,496          $ 1,114,844
Diluted Earnings Per Share $ 4.90      $ 0.26            $ 4.64

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
                 Three Months Ended September 30,
                   2012        2011       % Change
BD MEDICAL
 United States $ 422,290   $ 404,301    4.4
 International   626,742     650,290    (3.6)
TOTAL            $ 1,049,032 $ 1,054,591  (0.5)
BD DIAGNOSTICS
 United States $ 313,916   $ 313,603    0.1
 International   331,128     328,445    0.8
TOTAL            $ 645,044   $ 642,048    0.5
BD BIOSCIENCES
 United States $ 87,651    $ 96,543     (9.2)
 International   185,444     194,999    (4.9)
TOTAL            $ 273,095   $ 291,542    (6.3)
TOTAL REVENUES
 United States $ 823,857   $ 814,447    1.2
 International   1,143,314   1,173,734  (2.6)
TOTAL            $ 1,967,171 $ 1,988,181  (1.1)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
                 Twelve Months Ended September 30,
                   2012        2011       % Change
BD MEDICAL
 United States $ 1,685,101 $ 1,625,044  3.7
 International   2,405,592   2,382,260  1.0
TOTAL            $ 4,090,693 $ 4,007,304  2.1
BD DIAGNOSTICS
 United States $ 1,259,376 $ 1,245,872  1.1
 International   1,278,679   1,234,605  3.6
TOTAL            $ 2,538,055 $ 2,480,477  2.3
BD BIOSCIENCES
 United States $ 343,238   $ 376,639    (8.9)
 International   736,396     719,617    2.3
TOTAL            $ 1,079,634 $ 1,096,256  (1.5)
TOTAL REVENUES
 United States $ 3,287,715 $ 3,247,555  1.2
 International   4,420,667   4,336,482  1.9
TOTAL            $ 7,708,382 $ 7,584,037  1.6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)
                             United States
                                  2012            2011           % Change
BD MEDICAL
 Medical Surgical Systems  $    250,664    $    246,746        1.6
 Diabetes Care                  113,046         104,819        7.8
 Pharmaceutical Systems         58,580          52,736         11.1
TOTAL                        $    422,290    $    404,301        4.4
BD DIAGNOSTICS
 Preanalytical Systems     $    164,856    $    161,556        2.0
 Diagnostic Systems             149,060         152,047        (2.0)
TOTAL                        $    313,916    $    313,603        0.1
BD BIOSCIENCES (1)           $    87,651     $    96,543         (9.2)
TOTAL UNITED STATES          $    823,857    $    814,447        1.2
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced
Bioprocessing platform.
 Advanced Bioprocessing was previously reported with the Discovery Labware
unit.



BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
                     International
                                                     % Change
                         2012           2011         Reported   FXN   FX
                                                                        Impact
BD MEDICAL
 Medical Surgical  $   281,603     $  288,653      (2.4)        6.8   (9.2)
Systems
 Diabetes Care         120,391        119,832      0.5          9.8   (9.3)
 Pharmaceutical        224,748        241,805      (7.1)        5.3   (12.4)
Systems
TOTAL                $   626,742     $  650,290      (3.6)        6.8   (10.4)
BD DIAGNOSTICS
 Preanalytical     $   162,648     $  167,044      (2.6)        7.3   (9.9)
Systems
 Diagnostic            168,480        161,401      4.4          12.7  (8.3)
Systems
TOTAL                $   331,128     $  328,445      0.8          9.9   (9.1)
BD BIOSCIENCES (1)   $   185,444     $  194,999      (4.9)        3.5   (8.4)
TOTAL INTERNATIONAL  $   1,143,314   $  1,173,734    (2.6)        7.1   (9.7)
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced
Bioprocessing platform.
 Advanced Bioprocessing was previously reported with the Discovery Labware
unit.



BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
                     Total
                                                    % Change
                         2012          2011         Reported   FXN    FX
                                                                        Impact
BD MEDICAL
 Medical Surgical  $   532,267    $  535,399      (0.6)        4.4    (5.0)
Systems
 Diabetes Care         233,437       224,651      3.9          8.9    (5.0)
 Pharmaceutical        283,328       294,541      (3.8)        6.4    (10.2)
Systems
TOTAL                $   1,049,032  $  1,054,591    (0.5)        5.9    (6.4)
BD DIAGNOSTICS
 Preanalytical     $   327,504    $  328,600      (0.3)        4.7    (5.0)
Systems
 Diagnostic            317,540       313,448      1.3          5.6    (4.3)
Systems
TOTAL                $   645,044    $  642,048      0.5          5.1    (4.6)
BD BIOSCIENCES (1)   $   273,095    $  291,542      (6.3)        (0.7)  (5.6)
TOTAL REVENUES       $   1,967,171  $  1,988,181    (1.1)        4.7    (5.8)
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced
Bioprocessing platform.
 Advanced Bioprocessing was previously reported with the Discovery Labware
unit.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)
                          United States
                               2012              2011             % Change
BD MEDICAL
 Medical Surgical       $    977,999      $    980,326          (0.2)
Systems
 Diabetes Care               434,310           400,809          8.4
 Pharmaceutical Systems      272,792           243,909          11.8
TOTAL                     $    1,685,101    $    1,625,044        3.7
BD DIAGNOSTICS
 Preanalytical Systems  $    656,389      $    643,180          2.1
 Diagnostic Systems          602,987           602,692          0.0
TOTAL                     $    1,259,376    $    1,245,872        1.1
BD BIOSCIENCES (1)       $    343,238      $    376,639          (8.9)
TOTAL UNITED STATES       $    3,287,715    $    3,247,555        1.2
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced
Bioprocessing platform.
 Advanced Bioprocessing was previously reported with the Discovery Labware
unit.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
                     International
                                                      % Change
                         2012            2011         Reported   FXN  FX
                                                                        Impact
BD MEDICAL
 Medical Surgical  $   1,127,289   $   1,101,407    2.3          6.9  (4.6)
Systems
 Diabetes Care         476,966         465,668      2.4          6.8  (4.4)
 Pharmaceutical        801,337         815,185      (1.7)        4.4  (6.1)
Systems
TOTAL                $   2,405,592   $   2,382,260    1.0          6.1  (5.1)
BD DIAGNOSTICS
 Preanalytical     $   644,503     $   634,613      1.6          6.7  (5.1)
Systems
 Diagnostic            634,176         599,992      5.7          9.4  (3.7)
Systems
TOTAL                $   1,278,679   $   1,234,605    3.6          8.0  (4.4)
BD BIOSCIENCES (1)   $   736,396     $   719,617      2.3          5.8  (3.5)
TOTAL INTERNATIONAL  $   4,420,667   $   4,336,482    1.9          6.6  (4.7)
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced
Bioprocessing platform.
 Advanced Bioprocessing was previously reported with the Discovery Labware
unit.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
                     Total
                                                      % Change
                         2012            2011         Reported   FXN  FX
                                                                        Impact
BD MEDICAL
 Medical Surgical  $   2,105,288   $   2,081,733    1.1          3.6  (2.5)
Systems
 Diabetes Care         911,276         866,477      5.2          7.5  (2.3)
 Pharmaceutical        1,074,129       1,059,094    1.4          6.2  (4.8)
Systems
TOTAL                $   4,090,693   $   4,007,304    2.1          5.1  (3.0)
BD DIAGNOSTICS
 Preanalytical     $   1,300,892   $   1,277,793    1.8          4.3  (2.5)
Systems
 Diagnostic            1,237,163       1,202,684    2.9          4.7  (1.8)
Systems
TOTAL                $   2,538,055   $   2,480,477    2.3          4.5  (2.2)
BD BIOSCIENCES (1)  $   1,079,634   $   1,096,256    (1.5)        0.7  (2.2)
TOTAL REVENUES       $   7,708,382   $   7,584,037    1.6          4.3  (2.7)
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced
Bioprocessing platform.
 Advanced Bioprocessing was previously reported with the Discovery Labware
unit.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
SAFETY REVENUES
(Unaudited; Amounts in thousands)
                      Three Months Ended September 30,
                                               % Change
                        2012        2011       Reported  FXN   FX Impact
TOTAL SAFETY REVENUES
 United States      $ 291,046   $ 288,541    0.9         0.9   -
 International        215,595     209,209    3.1         12.7  (9.6)
TOTAL                 $ 506,641   $ 497,750    1.8         5.8   (4.0)
BY SEGMENT
 BD Medical         $ 250,676   $ 243,521    2.9         6.4   (3.5)
 BD Diagnostics       255,965     254,229    0.7         5.3   (4.6)
TOTAL                 $ 506,641   $ 497,750    1.8         5.8   (4.0)
                      Twelve Months Ended September 30,
                                               % Change
                        2012        2011       Reported  FXN   FX Impact
TOTAL SAFETY REVENUES
 United States      $ 1,149,220 $ 1,116,543  2.9         2.9   -
 International        833,886     754,739    10.5        15.6  (5.1)
TOTAL                 $ 1,983,106 $ 1,871,282  6.0         8.0   (2.0)
BY SEGMENT
 BD Medical         $ 966,452   $ 885,156    9.2         10.8  (1.6)
 BD Diagnostics       1,016,654   986,126    3.1         5.6   (2.5)
TOTAL                 $ 1,983,106 $ 1,871,282  6.0         8.0   (2.0)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY2012 Quarter-to-Date Reconciliation
(Unaudited; Amounts in millions, except per share data)
           Three Months Ended September 30,
                        Pension
             Reported                 Adjusted   Reported  Impairment   Adjusted  Adjusted
                        Settlement
             FY 2012    Charge^(1)   FY 2012    FY 2011   Charge^(2)   FY 2011   %Growth
Diluted
Earnings
per Share
from
Continuing $ 1.35     $ 0.07        $ 1.42     $ 1.29      0.03       $ 1.32      7.6%
Operations
^(1) Primarily represents a non-cash pension settlement charge associated with lump sum
benefit payments made from the Company's
 U.S. supplemental pension plan, as such payments exceeded the service and interest
components of the plan's pension cost for the year.
 The charge also included settlement losses associated with certain foreign pension
plans.
^(2)Represents a non-cash impairment charge resulting from thediscontinuance of a
research program within the Diagnostic Systems unit.
All figures rounded. Totals may not add due to rounding.



BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY2012 Year-to-Date Reconciliation
(Unaudited; Amounts in millions, except per share data)
           Twelve Months Ended September 30,
                        Pension
             Reported                 Adjusted   Reported   Impairment   Adjusted  Adjusted
                        Settlement
             FY 2012                 FY 2012    FY 2011    Charge^(2)   FY 2011   %Growth
                        Charge^(1)
Diluted
Earnings
per Share
from
Continuing $ 5.30     $ 0.06        $ 5.37     $ 5.31     $ 0.03       $ 5.33      0.8%
Operations
^(1) Primarily represents a non-cash pension settlement charge associated with lump sum
benefit payments made from the Company's
 U.S. supplemental pension plan, as such payments exceeded the service and interest
components of the plan's pension cost for the year.
 The charge also included settlement losses associated with certain foreign pension
plans.
^(2)Represents a non-cash impairment charge resulting from the
 discontinuance of a research program within the Diagnostic Systems unit.
All figures rounded. Totals may not add due to rounding.



BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Quarter-to-Date Fiscal 2012 Reconciliation - FX Impact
(Unaudited; Amounts in millions, except per share data)
            Three Months Ended September 30,
                                    Adjusted   Foreign
              Adjusted   Adjusted                            FXN       FXN
                                    Growth    Currency
              FY 2012    FY 2011    $          Translation   Change  Growth
REVENUES    $ 1,967    $ 1,988    $ (21)     $ (114)       $ 93        4.7%
Diluted
Earnings
per Share
from
Continuing  $ 1.42     $ 1.32     $ 0.10     $ (0.10)      $ 0.20      15.2%
Operations
FXN - Foreign Currency Neutral
All figures rounded. Totals may not add due to rounding.



BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Year-to-Date Fiscal 2012 Reconciliation - FX Impact
(Unaudited; Amounts in millions, except per share data)
           Twelve Months Ended September 30,
                                   Adjusted   Foreign
             Adjusted   Adjusted                            FXN        FXN
                                   Growth    Currency
             FY 2012    FY 2011    $          Translation   Change^  Growth
REVENUES   $ 7,708    $ 7,584    $ 124      $ (200)       $ 325        4.3%
Diluted
Earnings
per Share
from
Continuing $ 5.37     $ 5.33     $ 0.04     $ (0.21)      $ 0.25       4.7%
Operations
FXN - Foreign Currency Neutral
All figures rounded. Totals may not add due to rounding.



BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY2013 Outlook Reconciliation
                   EPS     Revenues
Growth             4-5%    2-3%
FX impact          (3%)    (1.5%)
FX neutral growth  7-8%    3.5%-4.5%
Device tax impact  (3%)
                   10-11%





SOURCE BD (Becton, Dickinson and Company)

Website: http://www.bd.com